Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
City of Hope Medical Center
Binhui Biopharmaceutical Co., Ltd.
City of Hope Medical Center
Fox Chase Cancer Center
M.D. Anderson Cancer Center
ProgenaBiome
Apollomics Inc.
Allarity Therapeutics
University of California, Davis
Mabwell (Shanghai) Bioscience Co., Ltd.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Open Innovation Partners, Inc.
Oshadi Drug Administration
Institut Claudius Regaud
Piramal Enterprises Limited
Piramal Enterprises Limited
GlaxoSmithKline